Skip to content

Dense Red Blood Cells in Sickle Cell Children

Quantitative and Prognostic Evaluation of Dense Red Blood Cells in Sickle Cell Children: Single-center Study From the Creteil (France) Pediatric Cohort

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02887118
Acronym
DREPADENSE
Enrollment
82
Registered
2016-09-01
Start date
2015-12-31
Completion date
2019-07-07
Last updated
2020-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle Cell Disease

Keywords

Erythrocytes, Sickle Cell Disease

Brief summary

Quantitative and prognostic evaluation of dense red blood cells in sickle cell children: preliminary single center study from the Creteil pediatric cohort.

Detailed description

An association between red blood cell density and hemolytic parameters, and clinical manifestations has been demonstrated in adults with sickle cell anemia. This factor has not been studied in children. The identification of predictive biomarkers of disease severity, especially of specific pediatric complications (cerebral vasculopathy, splenic sequestration, Dactylitis) would be useful for optimal care of the children and early intensification Red blood cell density might be one of these prognostic factors.

Interventions

None listed

Sponsors

Centre Hospitalier Intercommunal Creteil
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Months to 18 Years
Healthy volunteers
No

Inclusion criteria

* Age: 18 months-18 years * Patient with sickle cell disease namely SS, or S / Beta0 or S / Beta + * Patient regularly followed in the pediatric cohort of the CHI Creteil * Patient Hospitalized for an annual check-up * With or without intensification by Hydroxycarbamide * patient who haven't been transfused within 3 months * Whose parents have given their informed consent * Patients insured to the French social scheme

Exclusion criteria

* Sickle cell SC disease * Having received an allogeneic bone marrow transplantation * Under regular transfusion program * Having received a transfusion within 3 months

Design outcomes

Primary

MeasureTime frameDescription
number of dense red blood cells (DRBC)1 dayEvaluation of the number of dense red blood cells in the blood of affected children

Secondary

MeasureTime frameDescription
Number of patients with velocities > 200 cm/sec on transcranial doppler1 dayCerebral vasculopathy (correlation with patients with abnormal velocities on transcranial doppler (TCD)(\> 200 cm/sec) History of dactylitis History of ischemic lesions on magnetic resonance imaging (MRI)
Number of patients with history of acute splenic sequestration,1 day
Number of patients with history of acute chest syndrome1 day
Number of patients with History of dactylitis1 day
biological profile1 dayhemolytic parameters (LDH, bilirubin, Hemoglobin level)
Number of patients with history of ischemic lesions on magnetic resonance imaging (MRI)1 day
Number of patients with hydroxycarbamide treatment1 dayeffect of hydroxycarbamide on the % DRBC
Number of dense red blood cells1 daynumber of dense red blood cells in the pediatric population with no known blood condition
Number of patients with history of abnormal transcranial doppler (TCD) (≥ 200 cm/sec)1 day

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026